Search results
Start date:
Mar 29, 2025
End date:
Mar 31, 2025
ACC 2025 will take place from March 29th to 31st in Chicago, IL.The American College of Cardiology (ACC) is the premier professional organization for over 54,000 cardiovascular professionals worldwide. Leading the charge in health policy formation, standards, and guidelines, the ACC is dedicated to improving cardiovascular care through national registries and professional medical education…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Greg GuilloryTwo late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes…
View more
ACC 2025 Late-Breaking Science Collection
Video Series
Added:
9 months ago
Unpack ACC.25's Top Trials with View from the Thoraxcenter!Join Prof Nicolas Van Mieghem and Dr Joost Daemen from Erasmus MC, Rotterdam for a deep dive into the late-breaking data presented at ACC 2025.In this thought-provoking ACC 2025 wrap-up, delve into the nuances of the most impactful trials, gaining insights into their implications for current practice and future research directions.00:36 -…
View more
Added:
9 months ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the…
View more
Added:
9 months ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene…
View more
Added:
1 year ago
ACC 2024 — Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Dr James L. Januzzi (Massachusetts General Hospital & Harvard Medical School, US) to discuss the latest findings from the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure trial (ARISE-HF, Applied Therapeutics, Inc) (NCT04083339).This phase 3 multicenter, randomized,…
View more
Added:
6 months ago
In this short interview, we are joined by Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) to discuss the key updates and recommendations from the 2025 ACC Scientific Statement on the Management of Obesity in Adults with Heart Failure.Interview Questions:1. What is the current research landscape for heart failure patients with obesity?2. What are the new recommendations in this scientific…
View more
Added:
9 months ago
ACC 25 - Findings of the MIGHTy-Heart study shows no difference between mobile integrated healthcare and a traditional transitions of care coordinator approach in 30-day all-cause readmissions or health status.Dr Ruth Masterson Creber (Columbia University, New York, US) joins us onsite at ACC to discuss the findings from MIGHTy-Heart, a comparative effectiveness study that evaluated two different…
View more
ACC.24: Late-Breaking Science Video Collection
Video Series